We think the stake in wide-moat Sartorius contributes to Bio-Rad’s moat. Although Bio-Rad does not have a controlling stake, Sartorius accounts for approximately 40% of Bio-Rad’s fair value in our ...

Researchers at Sutter Health, led by Cheryl Stults, Ph.D., found that an innovative ambient artificial intelligence platform ...

Thanks to budget cuts, many potential insights and treatments needed to propel oncology forward will never be realized.

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

A new clinical trial shows the immunotherapy drug dostarlimab may eliminate the need for surgery and chemotherapy in certain ...

A new policy from the US National Institutes of Health (NIH) will end billions of dollars of funding to laboratories and ...

Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to recent findings by rare cancer researcher Dr. Taran Gujral, head of Fred Hutch's ...

Today, the vast majority of kids survive cancer, thanks to federally supported clinical trials, but their funding could be in ...

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Explore the evolving landscape of clinical trials in drug discovery and learn about recent breakthroughs transforming the ...